LGT Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
LGT Fund Management's VRTX Position: Q2 2026 in Review
LGT Fund Management reduced its Vertex Pharmaceuticals (VRTX) stake by 31% in Q2 2026, selling an estimated $699K and leaving 3,485 shares worth $1.73M. The position accounts for 0.07% of the portfolio, ranked #175.
LGT Fund Management first reported a position in VRTX in Q2 2024 and has held it in 6 quarters since. The position peaked at $2.26M in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- LGT Fund Management held 3,485 shares of Vertex Pharmaceuticals worth $1.73M as of Q2 2026.
- LGT Fund Management sold 1,578 Vertex Pharmaceuticals shares in Q2 2026, an estimated $699K.
- Vertex Pharmaceuticals made up 0.07% of LGT Fund Management's portfolio in Q2 2026, its #175 holding.
- LGT Fund Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
- LGT Fund Management's Vertex Pharmaceuticals position peaked at $2.26M in Q1 2026.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on LGT Fund Management's 13F filing for Q2 2026, filed 10 Aug 2026.